Biotech News

Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution

Amneal Pharmaceuticals (AMRX)Amneal Pharmaceuticals2026-06-04 12:00 ESTFDA / regulatory

AMRX (AMRX) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is amrx.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a global pharmaceutical company with generics, specialty products, and injectables. Its business is defined by scale, manufacturing, and portfolio breadth rather than early-stage biotech science.

Recent company news

AMRXAmneal Pharmaceuticals2026-07-17 12:00 EST

Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations

Stock data

Close: 18.09 USD
Market cap: 4.04B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States

Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution

Related news

Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations

Amneal and Adalvo Announce FDA Acceptance for Review of Two U.S. ANDAs for Generic Tirzepatide Autoinjector

Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®